BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1158 related articles for article (PubMed ID: 21840040)

  • 21. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
    Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
    Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can we identify the group of small invasive (T1a,b) breast cancers with minimal risk of axillary lymph node involvement? A pathohistological and DNA flow cytometric study.
    Bezić J; Samija-Projić I; Projić P; Ljubković J; Capkun V; Tomić S
    Pathol Res Pract; 2011 Jul; 207(7):438-42. PubMed ID: 21689895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers.
    Miglietta A; Toselli M; Ravarino N; Vencia W; Chiecchio A; Bozzo F; Motta M; Torchio B; Bocca C
    Expert Opin Ther Targets; 2010 Jul; 14(7):655-64. PubMed ID: 20536410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
    Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
    J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
    Thangarajah F; Vogel C; Pahmeyer C; Eichler C; Holtschmidt J; Ratiu D; Mallmann P; Malter W
    Anticancer Res; 2018 Oct; 38(10):6023-6026. PubMed ID: 30275235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and biological characteristics of breast cancer.
    Kocic B; Filipovic S; Petrovic B; Mijalkovic D; Rancic N; Poultsidi A
    J BUON; 2010; 15(4):660-7. PubMed ID: 21229626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
    Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential TAG-72 epitope expression in breast cancer and lymph node metastases: a marker of a more aggressive phenotype.
    Galietta A; Pizzi C; Pettinato G; Limite G; Sgambato A; Lamberti M; Muraro R; Formisano C; Pensabene M; Bianco AR; Mariani-Costantini R; Contegiacomo A
    Oncol Rep; 2002; 9(1):135-40. PubMed ID: 11748471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
    Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
    Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.
    Hashimoto K; Shimizu C; Tsuda H; Saji S; Osaki A; Shigekawa T; Aogi K
    Oncology; 2012; 82(3):168-74. PubMed ID: 22433454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.
    Tong LC; Nelson N; Tsourigiannis J; Mulligan AM
    Am J Surg Pathol; 2011 Apr; 35(4):545-52. PubMed ID: 21358301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer.
    Aurilio G; Monfardini L; Rizzo S; Sciandivasci A; Preda L; Bagnardi V; Disalvatore D; Pruneri G; Munzone E; Della Vigna P; Renne G; Bellomi M; Curigliano G; Goldhirsch A; Nolè F
    Acta Oncol; 2013 Nov; 52(8):1649-56. PubMed ID: 23327413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
    Iwase H; Kurebayashi J; Tsuda H; Ohta T; Kurosumi M; Miyamoto K; Yamamoto Y; Iwase T
    Breast Cancer; 2010 Apr; 17(2):118-24. PubMed ID: 19466512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.
    Sáez R; Molina MA; Ramsey EE; Rojo F; Keenan EJ; Albanell J; Lluch A; García-Conde J; Baselga J; Clinton GM
    Clin Cancer Res; 2006 Jan; 12(2):424-31. PubMed ID: 16428482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis.
    Tas F
    Onkologie; 2012; 35(3):95-8. PubMed ID: 22414972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vascular invasion in triple-negative carcinoma of the breast identified by endothelial lymphatic and blood vessel markers.
    Kuroda H; Nakai M; Ohnisi K; Ishida T; Kuroda M; Itoyama S
    Int J Surg Pathol; 2010 Oct; 18(5):324-9. PubMed ID: 21068066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
    Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis.
    Shinozaki M; Hoon DS; Giuliano AE; Hansen NM; Wang HJ; Turner R; Taback B
    Clin Cancer Res; 2005 Mar; 11(6):2156-62. PubMed ID: 15788661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lobular and non-lobular breast cancers differ regarding axillary lymph node metastasis: a cross-sectional study on 4,292 consecutive patients.
    Vandorpe T; Smeets A; Van Calster B; Van Hoorde K; Leunen K; Amant F; Moerman P; Deraedt K; Brouckaert O; Van Huffel S; Wildiers H; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2011 Jul; 128(2):429-35. PubMed ID: 21562708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.